Patient
|
Age (years)/sex
|
Disease duration (years)
|
Treatment
|
---|
1
|
54/M
|
5
|
Azathioprine, methylprednisolone
|
2
|
38/F
|
6
|
Hydroxychloroquine, salazopyrine
|
3
|
64/F
|
7
|
NSAID
|
4
|
43/F
|
5
|
NSAID
|
5
|
46/M
|
1
|
Salazopyrine
|
6
|
46/M
|
<1
|
Salazopyrine
|
7
|
52/M
|
11
|
NSAID
|
8
|
53/F
|
11
|
NSAID
|
9
|
49/M
|
10
|
NSAID
|
10
|
52/F
|
4
|
NSAID
|
11
|
69/F
|
36
|
Salazopyrine
|
12
|
65/F
|
<1
|
Untreated
|
13
|
35/M
|
<1
|
Untreated
|
14a
|
57/F
|
4
|
Methotrexate
|
15a
|
46/M
|
2
|
Anti-TNF, salazopyrine
|
16a
|
41/M
|
10
|
Salazopyrine
|
17a
|
41/M
|
13
|
Methotrexate
|
18a
|
60/M
|
2
|
Leflunomide
|
19a
|
43/F
|
5
|
Methotrexate
|
20b
|
63/M
|
17
|
Salazopyrine
|
21a,b
|
65/F
|
4
|
Salazopyrine, hydroxychloroquine
|
22b
|
62/F
|
12
|
Leflunomide
|
23b
|
54/F
|
17
|
Methylprednisolone
|
- aSynovial fluid sample. bSynovial tissue sample. F, female; M, male; NSAID, nonsteroidal anti-inflammatory drug; TNF, tumour necrosis factor.